| MeSH term | MeSH ID | Detail |
|---|---|---|
| Leukemia, Myelomonocytic, Acute | D015479 | 6 associated lipids |
| Uveal Neoplasms | D014604 | 3 associated lipids |
| Opioid-Related Disorders | D009293 | 5 associated lipids |
| Neuroendocrine Tumors | D018358 | 4 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Adenocarcinoma, Papillary | D000231 | 2 associated lipids |
| von Hippel-Lindau Disease | D006623 | 1 associated lipids |
| Cystadenocarcinoma, Mucinous | D018282 | 1 associated lipids |
| Cystadenocarcinoma, Serous | D018284 | 2 associated lipids |
| Thyroid Hormone Resistance Syndrome | D018382 | 1 associated lipids |
trichostatin A
Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.
Cross Reference
Introduction
To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with trichostatin A?
trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with trichostatin A
PubChem Associated disorders and diseases
What pathways are associated with trichostatin A
Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with trichostatin A?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with trichostatin A?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with trichostatin A?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with trichostatin A?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with trichostatin A?
Mouse Model
Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).
Xenograft Model
Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).
Cancer Model
Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with trichostatin A
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wang LG et al. | Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. | 2004 | Oncogene | pmid:15156193 |
| Cao K et al. | Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. | 2015 | Oncogene | pmid:25745993 |
| Ong DC et al. | LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer. | 2009 | Oncogene | pmid:19734946 |
| Konduri SD et al. | Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. | 2003 | Oncogene | pmid:12881707 |
| Mulholland NM et al. | Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation. | 2003 | Oncogene | pmid:12894222 |
| Augenlicht L et al. | Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. | 2003 | Oncogene | pmid:12902981 |
| Quan H et al. | Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. | 2014 | Oncogene | pmid:23770846 |
| Wu Y et al. | Negative regulation of bcl-2 expression by p53 in hematopoietic cells. | 2001 | Oncogene | pmid:11313951 |
| Rashid SF et al. | Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. | 2001 | Oncogene | pmid:11313934 |
| Krämer OH et al. | Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. | 2008 | Oncogene | pmid:17653085 |
| Lu Z et al. | E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. | 2006 | Oncogene | pmid:16158053 |
| Pulukuri SM et al. | Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. | 2009 | Oncogene | pmid:19503093 |
| Cras A et al. | Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. | 2007 | Oncogene | pmid:17213810 |
| Karagiannis TC et al. | Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. | 2007 | Oncogene | pmid:17213813 |
| Toyooka S et al. | Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. | 2002 | Oncogene | pmid:12082623 |
| Jang ER et al. | The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. | 2004 | Oncogene | pmid:14676837 |
| Campanero MR et al. | The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites. | 2008 | Oncogene | pmid:17724474 |
| López-Soto A et al. | HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. | 2009 | Oncogene | pmid:19430493 |
| Reid G et al. | Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. | 2005 | Oncogene | pmid:15870696 |
| Sengupta S et al. | Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. | 2011 | Oncogene | pmid:20856196 |
| Kim YB et al. | Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. | 1999 | Oncogene | pmid:10229197 |
| Suzuki M et al. | Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. | 2003 | Oncogene | pmid:14647463 |
| Coombes MM et al. | Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. | 2003 | Oncogene | pmid:14654786 |
| Chan AS et al. | Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. | 2003 | Oncogene | pmid:14534543 |
| Krishnan M et al. | HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. | 2010 | Oncogene | pmid:19881542 |
| Ibanez de Caceres I et al. | IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. | 2010 | Oncogene | pmid:20023704 |
| Lund P et al. | Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. | 2006 | Oncogene | pmid:16568090 |
| Lee SH et al. | Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. | 2009 | Oncogene | pmid:18850007 |
| Rhodes LV et al. | The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. | 2012 | Oncol. Rep. | pmid:21971930 |
| Kim SH et al. | Regulation of the HIF-1alpha stability by histone deacetylases. | 2007 | Oncol. Rep. | pmid:17273746 |
| Anh TD et al. | The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells. | 2012 | Oncol. Rep. | pmid:21993600 |
| Wang B et al. | Reversion of trichostatin A resistance via inhibition of the Wnt signaling pathway in human pancreatic cancer cells. | 2014 | Oncol. Rep. | pmid:25224651 |
| Wang JH et al. | HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells. | 2018 | Oncol. Rep. | pmid:29767267 |
| Ji M et al. | HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. | 2015 | Oncol. Rep. | pmid:25813246 |
| Shao G et al. | Inactivation of EGFR/AKT signaling enhances TSA-induced ovarian cancer cell differentiation. | 2017 | Oncol. Rep. | pmid:28393191 |
| Nakajima S et al. | Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231. | 2009 | Oncol. Rep. | pmid:19513516 |
| Zuo X et al. | Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI. | 2014 | Oncol. Rep. | pmid:24676336 |
| Yanada M et al. | Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. | 2005 | Oncol. Rep. | pmid:16142337 |
| Jia L et al. | Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miR‑375. | 2017 | Oncol. Rep. | pmid:27878285 |
| Zhang NH et al. | Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells. | 2016 | Oncol. Rep. | pmid:27373420 |
| Kang HR et al. | Butyrate-mediated acquisition of chemoresistance by human colon cancer cells. | 2016 | Oncol. Rep. | pmid:27277338 |
| Qiao F et al. | Enforced expression of RASAL1 suppresses cell proliferation and the transformation ability of gastric cancer cells. | 2012 | Oncol. Rep. | pmid:22825043 |
| Liu Z et al. | Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. | 2008 | Oncol. Rep. | pmid:18575731 |
| Wang SC et al. | Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1‑survivin downregulation at the late phase of treatment. | 2017 | Oncol. Rep. | pmid:28713892 |
| Puppin C et al. | Histone deacetylase inhibitors control the transcription and alternative splicing of prohibitin in thyroid tumor cells. | 2011 | Oncol. Rep. | pmid:21152868 |
| Androutsopoulos VP and Spandidos DA | Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity. | 2017 | Oncol. Rep. | pmid:29039546 |
| Zhang X et al. | Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. | 2006 | Oncol. Rep. | pmid:16865256 |
| Villanueva R et al. | Histone deacetylase 3 represses HTLV-1 tax transcription. | 2006 | Oncol. Rep. | pmid:16865259 |
| Seo JS et al. | Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A. | 2008 | Oncol. Rep. | pmid:18097580 |
| Meng CF et al. | Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells. | 2009 | Oncol. Rep. | pmid:19787243 |